阐明基于替西莫肽（L-BLP25）的联合疗法的药效学。
Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
作者信息
Kao Chiao-Jung, Wurz Gregory T, Schröder Andreas, Wolf Michael, Degregorio Michael W
机构信息
University of California, Davis; Department of Internal Medicine; Division of Hematology and Oncology; Sacramento, CA USA.
ImmunoOncology; Merck Serono Research; Merck KGaA, Germany.
出版信息
Oncoimmunology. 2013 Oct 1;2(10):e26285. doi: 10.4161/onci.26285. Epub 2013 Sep 12.
The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide provides superior benefits to Stage IIIa and IIIb non-small cell lung carcinoma patients as compared with sequential chemoradiotherapy followed by tecemotide. These clinical observations will be dissected in a transgenic model of lung cancer that we have recently established (hMUC1.Tg C57BL/6 mice).
最近完成的一项III期临床试验结果表明，与序贯放化疗后使用替西莫肽相比，同步放化疗后使用替西莫肽可为IIIa期和IIIb期非小细胞肺癌患者带来更大益处。这些临床观察结果将在我们最近建立的肺癌转基因模型（hMUC1.Tg C57BL/6小鼠）中进行剖析。
Zotero 插件